Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with once-a-day dose

Pfiz­er won’t be mov­ing a twice-dai­ly for­mu­la­tion of its oral GLP-1, danuglipron, in­to Phase III af­ter the drug trig­gered high rates of gas­troin­testi­nal side ef­fects, de­spite meet­ing the pri­ma­ry end­point of its mid-stage weight loss tri­al.

The com­pa­ny is now pin­ning its hopes on a once-dai­ly for­mu­la­tion of danuglipron, which is in Phase I stud­ies with phar­ma­co­ki­net­ic da­ta ex­pect­ed in the first half of next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.